Editas Medicine, Inc. (EDIT) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Editas Medicine, Inc. (EDIT) stock forecast summary
Our AI ranks Editas Medicine, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Editas Medicine, Inc. is a small-cap company with a market capitalization of $361M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
For EDIT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 20.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, EDIT included.
Follow EDIT freeEDIT price chart and AI forecast
How EDIT ranks among 5184 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Editas Medicine, Inc. (EDIT) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | EDIT | Rank |
|---|---|---|
| Market Cap | $361M | 60/60 |
| P/B Ratio | 3.43x | 31/50 |
| EPS | $-1.32 | – |
| Book Value/Share | $0.69 | – |
| Revenue/Share | $0.29 | – |
| FCF/Share | $-0.78 | – |
Profitability & Margins
| Metric | EDIT | Rank |
|---|---|---|
| ROIC | -44.9% | 39/53 |
| Operating Margin | -171.7% | 25/40 |
| EBT Margin | -171.7% | 26/42 |
Financial Health
| Metric | EDIT | Rank |
|---|---|---|
| Current Ratio | 3.19x | 45/59 |
| D/E Ratio | 1.25x | 11/53 |
| Financial Leverage | 2.25x | 11/52 |
| Interest Coverage | -17.5x | 20/38 |
| Working Capital | $150M | 53/59 |
Cash Flow
| Metric | EDIT | Rank |
|---|---|---|
| Operating Cash Flow | -$120M | 28/57 |
| Free Cash Flow | -$121M | 26/50 |
| Capital Spending | -$690K | 7/50 |
| FCF/Sales | -272.9% | 26/32 |
| CapEx/Sales | 1.6% | 26/32 |
Operational Efficiency
| Metric | EDIT | Rank |
|---|---|---|
| Asset Turnover | 0.19x | 24/36 |
| Receivables Turnover | 16.2x | 4/24 |
| Fixed Assets Turnover | 17.2x | 9/37 |
| Days Sales Outstanding | 23 days | 21/24 |
Income Statement
| Metric | EDIT | Rank |
|---|---|---|
| Total Revenue | $44M | 30/37 |
| Operating Income | -$76M | 20/54 |
| R&D Expense | $85M | 47/56 |
Dividend & Shareholder Information
| Metric | EDIT | Rank |
|---|---|---|
| Shares Outstanding | 154M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $218M | 91.9% of assets |
| Cash & Short-term Investments | $182M | 76.6% of assets |
| Accounts Receivable | $3M | 1.2% of assets |
| Total Liabilities | $132M | 55.7% of assets |
| Short-term Debt | $64M | 26.8% of assets |
EDIT quarterly financials and insider trading
Editas Medicine, Inc. (EDIT) industry peers
Companies classified under the same SEC industry code as Editas Medicine, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| EDIT Editas Medicine, Inc. | ▲ | $361M |
| AMGN Amgen Inc | ▼ | $233.82B |
| GILD Gilead Sciences, Inc. | ▶ | $193.67B |
| MRNA Moderna, Inc. | ▲ | $87.04B |
| ARGX Argenx Se | ▼ | $50.69B |
| RVMD Revolution Medicines, Inc. | ▲ | $38.14B |
| BIIB Biogen Inc. | ▼ | $34.13B |
| BNTX Biontech Se | ▲ | $22.18B |
| EXEL Exelixis, Inc. | ▼ | $15.42B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.83B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.79B |
| TECH Bio-Techne Corp | ▼ | $11.38B |
| QGEN Qiagen N.V. | ▶ | $10.01B |
| RGEN Repligen Corp | ▲ | $9.90B |
| IBRX Immunitybio, Inc. | ▲ | $9.73B |
| PCVX Vaxcyte, Inc. | ▲ | $9.47B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.37B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.71B |
| TWST Twist Bioscience Corp | ▲ | $8.32B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.17B |
| IMVT Immunovant, Inc. | ▲ | $5.52B |
| KOD Kodiak Sciences Inc. | ▲ | $5.39B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.86B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.76B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.83B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.57B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $2.99B |
| DNLI Denali Therapeutics Inc. | ▶ | $2.81B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.42B |
| ADMA Adma Biologics, Inc. | ▼ | $2.39B |
| LIFE Atyr Pharma Inc | ▲ | $2.37B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.07B |
| VCEL Vericel Corp | ▶ | $2.05B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $1.99B |
| NVAX Novavax Inc | ▲ | $1.86B |
| ALVO Alvotech | ▲ | $1.78B |
| MESO Mesoblast Ltd | ▶ | $1.70B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.69B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B |
| IMCR Immunocore Holdings Plc | ▼ | $1.51B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.40B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.18B |
| VOR Vor Biopharma Inc. | ▲ | $1.07B |
| REPL Replimune Group, Inc. | ▲ | $1.02B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $902M |
| MGTX Meiragtx Holdings Plc | ▶ | $891M |
| SLBT Sl Science Holding Ltd | ▶ | $873M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $832M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $831M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $825M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $692M |
| SANA Sana Biotechnology, Inc. | ▲ | $680M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $670M |
| AURA Aura Biosciences, Inc. | ▲ | $633M |
| PRME Prime Medicine, Inc. | ▲ | $629M |
| CADL Candel Therapeutics, Inc. | ▲ | $627M |
| SLDB Solid Biosciences Inc. | ▲ | $593M |
| DBVT Dbv Technologies S.A. | ▶ | $536M |
Where EDIT sits on the market map
Editas Medicine, Inc. (EDIT) stock news
Loading...
Editas Medicine, Inc. (EDIT) stock forecast FAQ
What is the Editas Medicine, Inc. (EDIT) stock forecast?
Our AI ranks Editas Medicine, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Editas Medicine, Inc. stock predictions?
For EDIT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 20.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Editas Medicine, Inc. forecasts updated?
Editas Medicine, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Editas Medicine, Inc.'s industry peers?
60 issuers in our coverage, EDIT included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.